UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008359
Receipt number R000008844
Scientific Title Exploratory Study of Usefulness of 18F-BPA PET/CT in Clinical Staging of Malignancies
Date of disclosure of the study information 2012/07/17
Last modified on 2020/01/10 12:27:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory Study of Usefulness of 18F-BPA PET/CT in Clinical Staging of Malignancies

Acronym

Study of Usefulness of 18F-BPA PET/CT

Scientific Title

Exploratory Study of Usefulness of 18F-BPA PET/CT in Clinical Staging of Malignancies

Scientific Title:Acronym

Study of Usefulness of 18F-BPA PET/CT

Region

Japan


Condition

Condition

patients with malignancies

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To confirm safety of F18-BPA PET/CT and to explore its usefulness in the diagnosis of malignancies

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I,II


Assessment

Primary outcomes

Safety of F18-BPA
Biodistribution of F18-BPA
Optimal imaging conditions of F18-BPA PET/CT

Key secondary outcomes

Comparison of F18-BPA and F18-FDG PET/CT
Comparison and evaluation of F18-BPA accumulations in the target lesions and their clinical characteristics


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

Injection of 3.7-5.55MBq/kg F18-BPA and PET/CT imaging study of 4 hours and blood examinations, and conventional F18-FDG PET/CT examination

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

2 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Written informed consent can be obtained
Equal to or over 2 years and less tha 80 years
Established diagnosis of malignancy by histology or cytology with evaluable lesions
PS is 0-2
Quiet supine position can be kept during PET/CT examinations
F18-FDG PET/CT can be performed within 2 weeks of F-18-BPA PET/CT
Main organs functions must be normal
EKG before F18-BPA injection must be normal


Key exclusion criteria

entered or entering to other clinical trials within 3 months
Patients with uncontrollable diabetes or hypertension, with phenylketonuria, unstable angina, chronic renal disease or renal failure
Patients who cannot undergo F18-FDG PET/CT
Pregnant women or women who have the possibility to be pregnant
Lactating women
Patient who wants the partner be pregnant
Patients with mental disorders whose entry to the clinical trial seems diffucult
Patients who are considered to be ineligible by referring physician

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Jun ITAMI

Organization

National Cancer Center Hospital

Division name

Department of Radiation Oncology

Zip code


Address

Tsukiji 5-1-1, Chuo-ku, Tokyo

TEL

03-3542-2511

Email

jitami@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Jun ITAMI

Organization

National Cancer Center Hospital

Division name

Department of Radiation Oncology

Zip code


Address

Tsukiji 5-1-1, Chuo-ku, Tokyo

TEL

03-3542-2511

Homepage URL


Email

jitami@ncc.go.jp


Sponsor or person

Institute

"Hotta Group" of National Cancer Center Cancer Research and Development Fund

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center Cancer Research and Development Fund

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

2011-165

Org. issuing International ID_1

National Cancer Center

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター中央病院(東京都)
National Cancer Center Hospital (Tokyo)


Other administrative information

Date of disclosure of the study information

2012 Year 07 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 02 Month 27 Day

Date of IRB

2012 Year 01 Month 01 Day

Anticipated trial start date

2012 Year 03 Month 01 Day

Last follow-up date

2019 Year 02 Month 01 Day

Date of closure to data entry

2019 Year 02 Month 01 Day

Date trial data considered complete


Date analysis concluded

2019 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 07 Month 05 Day

Last modified on

2020 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008844


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name